News

ANX1502 proof-of-concept trial to wrap up next year, Annexon says

A proof-of-concept study designed to test a new tablet formulation of the experimental therapy ANX1502 in people with cold agglutinin disease (CAD) is continuing dosing to provide further insights into the therapy’s pharmacological profile and its impact on disease biomarkers. Data so far have been promising, showing that blood…

Iptacopan rapidly stops red blood cell damage in rare CAD case

A 44-year-old man with cold agglutinin disease (CAD) secondary to lymphoplasmacytic lymphoma, a type of blood cancer, recovered quickly after starting iptacopan, an oral therapy that targets the complement system, together with lymphoma treatment, a study showed. The complement cascade is a part of the immune system that contributes…

CAD develops secondary to leukemia in man, 64: Case study

A 64-year-old man in Iran developed cold agglutinin disease (CAD) secondary to acute myeloid leukemia (AML), a type of blood cancer, a case study reports. The blood cancer was detected only after the man started to experience CAD symptoms and a biopsy of the bone marrow, the spongy tissue in which…

Unique immune features found in AIHA may provide drug targets

While autoimmune hemolytic anemia (AIHA) — a group of disorders that includes cold agglutinin disease (CAD) — shares some immune features with other red blood cell-targeting diseases, its unique features might help researchers develop targeted therapies, a study reports. When analyzing the repertoire of immune B- and T-cell receptor…

Researchers call for standard antibody tests to diagnose CAD

Laboratories testing for cold agglutinins — the self-reactive antibodies causing cold agglutinin disease (CAD) — need to use standard protocols to provide accurate results, compare results between studies, and guide treatment, researchers said. “International standardization of CA [cold agglutinin] testing for diagnostic use is essential,” the researchers wrote.

Glucocorticoid therapy successfully treats man’s CAD: Case study

The glucocorticoid prednisolone successfully treated a man’s primary cold agglutinin disease (CAD), which is typically resistant to such therapies, a case report said. “Occasional” primary CAD cases “have demonstrated a favorable response” to glucocorticoids, “highlighting the need for a flexible and individualized therapeutic approach,” the researchers wrote. The case…

Enjaymo prior to major surgery can prevent CAD complications: Case

In people with cold agglutinin disease (CAD), pretreatment with Enjaymo (sutimlimab-jome) may limit disease-associated complications following urgent or planned surgeries in which a patient’s body temperature is considerably decreased. That’s according to a new report detailing the case of an 80-year-old woman in Japan for whom Enjaymo treatment before an…